AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- Study findings suggest p53 genetic polymorphism at codon 72 is associated with estrogen receptor positive breast cancer risk in Japanese women.
"Since it is well established that inactivation of p53 is involved in pathogenesis of breast cancer, it seems to be reasonable to assume that p53 genetic polymorphism at codon 72 [p53(Arg72Pro)], which affects the function of p53, might have an influence on breast cancer risk," said C. Noma and colleagues, Osaka University. "Thus, in the present study, we have studied the association of p53(Arg72Pro) polymorphism with breast cancer risk."
The researchers conducted "a case-control study . . . with 191 breast cancer patients and 218 healthy female controls. p53(Arg72Pro) polymorphism was examined in their association with breast cancer risk after adjustment for the epidemiological risk factors."
"Relationship between p53(Arg72Pro) polymorphism and clinicopathological characteristics of breast cancers was also studied," they said, and "[i]n addition, frequency of somatic p53 mutation was compared according to the genotype of p53(Arg72Pro) polymorphism."
Noma and colleagues reported that "p53(72Pro/Pro) homozygotes showed a significant increase in the risk of estrogen receptor (ER)-positive breast cancer (adjusted odds ratio (OR) = 2.04, p=.04) as compared with p53(72Arg/Arg) homozygotes, whereas such an association was not found between p53(72Pro/Pro) homozygotes and ER-negative breast cancer risk."
When the researchers looked at their data according to menopausal status, they found "that p53(72Pro/Pro) homozygotes were significantly associated with ER-positive breast cancer risk in postmenopausal women (adjusted OR = 3.42, p=.01) but not ...